×
Ardelyx Receivables 2013-2025 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ardelyx receivables from 2013 to 2025. Receivables can be defined as the total amount of collectibles for a company
View More
Ardelyx Receivables 2013-2025 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ardelyx receivables from 2013 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.6B
Zoetis (ZTS)
$69B
Takeda Pharmaceutical (TAK)
$46.7B
Daiichi Sankyo, - (DSNKY)
$41.7B
BeOne Medicines - (ONC)
$27.4B
Sandoz Group AG (SDZNY)
$24.6B
Summit Therapeutics (SMMT)
$18.6B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.3B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.3B
Stevanato Group S.p.A (STVN)
$7.6B
Corcept Therapeutics (CORT)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7B
Grifols, S.A (GRFS)
$6.7B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.1B
Crinetics Pharmaceuticals (CRNX)
$3B
Hypermarcas (HYPMY)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.4B
Centessa Pharmaceuticals (CNTA)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.7B